This page lists the SEC filings reported by Broadfin Capital, LLC.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2017-01-13 | Broadfin Capital, LLC | DERMA SCIENCES, INC. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2017-01-09 | Broadfin Capital, LLC | Mirati Therapeutics, Inc. | 826,001 | 4.2% | EDGAR |
| SC 13G | 2017-01-09 | Broadfin Capital, LLC | Mirati Therapeutics, Inc. | 1,676,001 | 6.9% | EDGAR |
| SC 13G/A | 2017-01-06 | Broadfin Capital, LLC | AVADEL PHARMACEUTICALS PLC | 0 | 0.0% | EDGAR |
| SC 13G | 2017-01-06 | Broadfin Capital, LLC | AVADEL PHARMACEUTICALS PLC | 4,394,464 | 10.7% | EDGAR |
| SC 13D/A | 2016-12-14 | Broadfin Capital, LLC | Recro Pharma, Inc. | 3,100,086 | 16.4% | EDGAR |
| SC 13D/A | 2016-12-01 | Broadfin Capital, LLC | Aegerion Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2016-12-01 | Broadfin Capital, LLC | QLT INC/BC | 9,742,770 | 10.5% | EDGAR |
| SC 13G | 2016-11-21 | Broadfin Capital, LLC | DURECT CORP | 8,506,229 | 6.1% | EDGAR |
| SC 13G | 2016-11-04 | Broadfin Capital, LLC | VERACYTE, INC. | 1,916,666 | 5.8% | EDGAR |
| SC 13D/A | 2016-09-22 | Broadfin Capital, LLC | QLT INC/BC | 5,269,831 | 10.0% | EDGAR |
| SC 13D/A | 2016-09-13 | Broadfin Capital, LLC | QLT INC/BC | 4,445,527 | 8.4% | EDGAR |
| SC 13D/A | 2016-09-13 | Broadfin Capital, LLC | Aegerion Pharmaceuticals, Inc. | 4,286,291 | 14.5% | EDGAR |
| SC 13D/A | 2016-08-17 | Broadfin Capital, LLC | Recro Pharma, Inc. | 2,450,086 | 20.7% | EDGAR |
| SC 13G | 2016-08-10 | Broadfin Capital, LLC | Mirati Therapeutics, Inc. | 1,000,000 | 5.0% | EDGAR |
| SC 13D | 2016-06-22 | Broadfin Capital, LLC | QLT INC/BC | 4,445,527 | 8.4% | EDGAR |
| SC 13D | 2016-06-22 | Broadfin Capital, LLC | Aegerion Pharmaceuticals, Inc. | 4,010,291 | 13.6% | EDGAR |
| SC 13G | 2016-03-24 | Broadfin Capital, LLC | Aralez Pharmaceuticals Inc. | 3,800,000 | 5.9% | EDGAR |
| SC 13D/A | 2016-03-15 | Broadfin Capital, LLC | STRATA Skin Sciences, Inc. | 1,008,297 | 9.9% | EDGAR |
| SC 13G/A | 2016-03-08 | Broadfin Capital, LLC | PERNIX THERAPEUTICS HOLDINGS, INC. | 6,090,829 | 10.0% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.